R
Rosemarie D. Mason
Researcher at National Institutes of Health
Publications - 45
Citations - 1224
Rosemarie D. Mason is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Simian immunodeficiency virus & Epitope. The author has an hindex of 17, co-authored 38 publications receiving 817 citations. Previous affiliations of Rosemarie D. Mason include University of Melbourne & Vaccine Research Center.
Papers
More filters
Journal ArticleDOI
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants.
Lingshu Wang,Tongqing Zhou,Yi Zhang,Eun Sung Yang,Chaim A. Schramm,Wei Shi,Amarendra Pegu,Olamide K. Oloniniyi,Amy R. Henry,Samuel Darko,Sandeep Narpala,Christian Hatcher,David R. Martinez,Yaroslav Tsybovsky,Emily Phung,Olubukola M. Abiona,Avan Antia,Evan M. Cale,Lauren A. Chang,Misook Choe,Kizzmekia S. Corbett,Rachel L. Davis,Anthony T. DiPiazza,Ingelise J. Gordon,Sabrina Helmold Hait,Tandile Hermanus,Tandile Hermanus,Prudence Kgagudi,Prudence Kgagudi,Farida Laboune,Kwanyee Leung,Tracy Liu,Rosemarie D. Mason,Alexandra Nazzari,Laura Novik,Sarah O’Connell,Sijy O'Dell,Adam S. Olia,Stephen D. Schmidt,Tyler Stephens,Christopher D. Stringham,Chloe Adrienna Talana,I-Ting Teng,Danielle A. Wagner,Alicia T. Widge,Baoshan Zhang,Mario Roederer,Julie E. Ledgerwood,Tracy J. Ruckwardt,Martin R. Gaudinski,Penny L. Moore,Penny L. Moore,Nicole A. Doria-Rose,Ralph S. Baric,Barney S. Graham,Adrian B. McDermott,Daniel C. Douek,Peter D. Kwong,John R. Mascola,Nancy J. Sullivan,John Misasi +60 more
TL;DR: This paper identified four receptor binding domain-targeting antibodies from three early-outbreak convalescent donors with potent neutralizing activity against 23 variants of SARS-CoV-2 variants of concern (VOCs).
Journal ArticleDOI
Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape.
Lingshu Wang,Wei Shi,James D. Chappell,M. Gordon Joyce,Yi Zhang,Masaru Kanekiyo,Michelle M. Becker,Neeltje van Doremalen,Robert S. Fischer,Nianshuang Wang,Kizzmekia S. Corbett,Misook Choe,Rosemarie D. Mason,Joseph Van Galen,Tongqing Zhou,Kevin O. Saunders,Kathleen M. Tatti,Lia M. Haynes,Peter D. Kwong,Kayvon Modjarrad,Wing-Pui Kong,Jason S. McLellan,Mark R. Denison,Vincent J. Munster,John R. Mascola,Barney S. Graham +25 more
TL;DR: It is shown that antibody responses to multiple domains on CoV spike protein may improve immunity and will guide future vaccine and therapeutic development efforts and that combining RBD- and non-RBD MAbs delayed the emergence of escape mutations in a cell-based virus escape assay.
Journal ArticleDOI
Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV
Mario Roederer,Brandon F. Keele,Stephen D. Schmidt,Rosemarie D. Mason,Hugh C. Welles,Hugh C. Welles,Will Fischer,Celia C. LaBranche,Kathryn E. Foulds,Mark K. Louder,Zhi-Yong Yang,Zhi-Yong Yang,John Paul Todd,Adam P. Buzby,Linh Mach,Ling Shen,Kelly E. Seaton,Brandy M. Ward,Robert T. Bailer,Raphael Gottardo,Wenjuan Gu,Guido Ferrari,S. Munir Alam,Thomas N. Denny,David C. Montefiori,Georgia D. Tomaras,Bette T. Korber,Martha Nason,Robert A. Seder,Richard A. Koup,Norman L. Letvin,Srinivas S. Rao,Gary J. Nabel,Gary J. Nabel,John R. Mascola +34 more
TL;DR: A nonhuman primate challenge model with simian immunodeficiency virus (SIV) shows that antibodies to the SIV envelope are necessary and sufficient to prevent infection, and identifies a two-amino-acid signature that alters antigenicity and confers neutralization resistance.
Journal ArticleDOI
Control of Viremia and Prevention of AIDS following Immunotherapy of SIV-Infected Macaques with Peptide-Pulsed Blood
Robert De Rose,Caroline S. Fernandez,Miranda Zoe Denham Smith,C. Jane Batten,Sheilajen Alcântara,Vivienne Peut,Erik Rollman,Liyen Loh,Rosemarie D. Mason,Kim Wilson,Matthew Law,Amanda J. Handley,Stephen J. Kent +12 more
TL;DR: High-level, SIV-specific CD4 and CD8 T-cell immunity was induced following immunization, both during antiretroviral cover and without, and a significant delay in AIDS-related mortality resulted.
ComponentDOI
Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization
Rui Kong,Hongying Duan,Zizhang Sheng,Kai Xu,Priyamvada Acharya,Xuejun Chen,Cheng Cheng,Adam S. Dingens,Jason Gorman,Mallika Sastry,Chen-Hsiang Shen,Baoshan Zhang,Tongqing Zhou,Gwo-Yu Chuang,C.W. Chao,Ying Gu,Alexander J. Jafari,Mark K. Louder,Sijy O'Dell,A.P. Rowshan,E.G. Viox,Yiran Wang,C.W. Choi,Martin Corcoran,A.R. Corrigan,Venkata P. Dandey,Edward T. Eng,Hui Geng,Kathryn E. Foulds,Yicheng Guo,Young Do Kwon,B. Lin,Kevin Liu,Rosemarie D. Mason,Martha Nason,T.Y. Ohr,L. Ou,Reda Rawi,E.K. Sarfo,Arne Schön,John Paul Todd,S. Wang,Hui Wei,W. Wu,James C. Mullikin,Robert T. Bailer,Nicole A. Doria-Rose,G.B. Karlsson Hedestam,Diana G. Scorpio,Julie Overbaugh,Jesse D. Bloom,Bridget Carragher,Clint Potter,L. Shapiro,Peter D. Kwong,Peter D. Kwong,John R. Mascola +56 more
TL;DR: Five neutralizing Ab lineages targeting the HIV-1-fusion peptide in vaccinated macaques over time were identified, characterized, and tracked, revealing two to belong to a reproducible class capable of neutralizing up to 59% of 208 diverse viral strains.